Lyra Therapeutics

## Lyra Therapeutics: Delivering Targeted Relief for Chronic Rhinosinusitis Lyra Therapeutics is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts. The company focuses on developing innovative therapies for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting the paranasal sinuses. With a team of 63 employees, Lyra Therapeutics is dedicated to improving the lives of patients suffering from this chronic condition. Lyra Therapeutics' innovative approach centers around proprietary technology designed to deliver medications directly and consistently to the affected tissue for extended periods. Their product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended to deliver mometasone furoate, a potent corticosteroid, directly to the sinonasal passages. This targeted delivery method aims to provide up to six months of continuous drug therapy with a single, in-office procedure. The company's commitment to precision medicine and sustained drug delivery sets them apart in the treatment of CRS. By focusing on localized therapy, Lyra Therapeutics seeks to minimize systemic side effects often associated with traditional treatment options. Their innovative approach holds significant promise for patients seeking long-lasting relief from the debilitating symptoms of CRS. For more information about Lyra Therapeutics and their groundbreaking therapies, please visit their website at lyratx.com.